Can gene therapy cure sickle cell disease?

Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Adam reports back from the nation’s biggest hematology conference on an early but promising gene therapy that could end up being a cure for sickle cell. Then, STAT biotech correspondent Meghana Keshavan joins us to break down the strange case of a recently approved drug that has some patients up in arms. And then we dive into that aforementioned Moderna IPO and explain what it means for the whole drug industry.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.